The growing pressure on drug companies to bring new rare disease therapies quickly and cost-effectively is giving rise to a variety of emerging business models. While there are a number of fully integrated pharmaceutical companies in the space, others are focusing on licensing a platform technology, acting more like an incubator, or driving an array of projects through a collaboration model. What do companies gain or lose through such strategies? How do they accelerate the development of new therapies? How do investors view these models?
Get the latest news as it happens.